ArticleJournal of clinical immunology2022

Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant.

Hannes Lindahl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.